AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [3] - The company's lead product is Ampligen (rintatolimod), a first-in-class investigational drug that acts as a dsRNA and highly selective TLR3 agonist immuno-modulator, showing broad spectrum activity in clinical trials [3] Upcoming Event - AIM will participate in the Corporate Connect Webinar Series hosted by Webull Financial on February 10-11, 2026 [1] - Thomas K. Equels, the CEO of AIM, will provide a corporate overview and business outlook, with a focus on the company's strategic emphasis on pancreatic cancer [1] - The presentation is scheduled for February 11, 2026, at 1:40 PM EST [1]